LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Harmony Biosciences Holdings Inc

Open

BrancheGesundheitswesen

34.64 0.03

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.54

Max

35.73

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.4M

49M

Verkäufe

15M

201M

KGV

Branchendurchschnitt

12.08

54.379

EPS

1.08

Gewinnspanne

24.582

Angestellte

268

EBITDA

-6.2M

66M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+49.78% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-209M

1.7B

Vorheriger Eröffnungskurs

34.61

Vorheriger Schlusskurs

34.64

Nachrichtenstimmung

By Acuity

50%

50%

198 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2025, 22:34 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12. Mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12. Mai 2025, 23:46 UTC

Market Talk

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12. Mai 2025, 23:34 UTC

Market Talk

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12. Mai 2025, 23:21 UTC

Market Talk

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12. Mai 2025, 22:54 UTC

Market Talk

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12. Mai 2025, 22:43 UTC

Ergebnisse

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12. Mai 2025, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12. Mai 2025, 22:07 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12. Mai 2025, 22:07 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Australia Retail Electricity Business to AGL

12. Mai 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12. Mai 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12. Mai 2025, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12. Mai 2025, 22:04 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12. Mai 2025, 21:15 UTC

Top News

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12. Mai 2025, 21:01 UTC

Ergebnisse

Constellation Software 1Q Rev $2.65B >CSU.T

12. Mai 2025, 21:01 UTC

Ergebnisse

Constellation Software 1Q Net $115M >CSU.T

12. Mai 2025, 21:01 UTC

Ergebnisse

Constellation Software 1Q EPS $5.44 >CSU.T

12. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. Mai 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

12. Mai 2025, 20:44 UTC

Top News

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12. Mai 2025, 20:31 UTC

Top News

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12. Mai 2025, 20:24 UTC

Ergebnisse

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12. Mai 2025, 20:24 UTC

Ergebnisse

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12. Mai 2025, 20:24 UTC

Top News

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12. Mai 2025, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12. Mai 2025, 20:15 UTC

Ergebnisse

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12. Mai 2025, 20:10 UTC

Ergebnisse

Blink Charging 1Q Rev $20.8M >BLNK

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

49.78% Vorteil

12-Monats-Prognose

Durchschnitt 51 USD  49.78%

Hoch 70 USD

Tief 31 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

6

Buy

0

Halten

1

Sell

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Very Strong Bearish Evidence

Stimmung

By Acuity

198 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.